A new paradigm in cancer treatment – combining the effectiveness of targeted therapy and immunotherapy

A new paradigm in cancer treatment – combining the effectiveness of targeted therapy and immunotherapy

Archive - 2013

Karus Therapeutics Appoints Penelope Ward as CMO

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced that Penelope Ward has joined the Company in the role of Chief Medical Officer. Her appointment strengthens the Company’s expansion which recently saw the formation of a Scientific Advisory Board, appointment of additional R&D personnel and a move to a world-class biotech hub near Oxford.

Karus Therapeutics wins ‘Best Biotech Fundraiser’ award

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has won ‘Best Biotech Fundraiser’ at this year’s OBN Awards ahead of shortlisted candidates e-Therapeutics and Heptares Therapeutics.

Karus Therapeutics shortlisted for key industry award

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, is shortlisted for the ‘Best Biotech Fundraiser’ at this year’s OBN Awards. The awards will be held on the 1st October 2013 at the Ashmolean Museum in Oxford and will bring together the UK's emerging life sciences companies, corporate partners and investors to celebrate the achievements within the bioscience sector over the last year. To read more about the OBN Awards, please follow the link here.

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced its engagement with the “Epigenetics’ Second Wind” debate at the SciBX Summit on Innovation in Drug Discovery and Development to be held in Boston, USA, on 29-30 October.

Karus Therapeutics interviewed by Pharma Television

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, was interviewed about its pioneering work in the HDAC and PI3K arena. Dr Simon Kerry, Karus’s CEO discussed the Company’s plans to develop current programmes using its substantial financing backing with Pharma Television’s Fintan Walton at the 10th Anglonordic Biotech Conference, London, UK. To watch the interview, please follow the link here.

Karus Therapeutics features on BBC South News

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, was featured on BBC South Today to highlight the importance of attracting venture capital financing to support the research and development of early stage biotechnology companies in the Oxfordshire area. The news story included filming at the new Karus laboratories in Milton Park and interviews with Dr Simon Kerry, CEO and Dr Stephen Shuttleworth, CSO.

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be making presentations at a number of key trade conferences including:

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced the appointment of its scientific advisory board (SAB), which brings together world-leading expertise in target biology and drug research and development. The appointment of Karus’s SAB reflects the Company’s recent expansion and move to fully-integrated research and office facilities near Oxford.